Clinical Trial

Ivonescimab for the Treatment of Thymic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-12; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-07-25
Trial Details
NCT Number NCT06980077
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Summit Therapeutics
Conditions Thymus Carcinoma
Enrollment 25 participants
Start Date 2025-07-15
Primary Completion 2027-06-17 (estimated)
Study Completion 2028-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-07